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Abstract
Background: The incidence of asthma is increasing at an alarming rate and while the current available therapies
are effective in the majority of patients they fail to adequately control symptoms at the more severe end of the
disease spectrum. In the search to understand disease pathogenesis and find effective therapies animal models are
often employed. As exposure to house dust mite (HDM) has a causative link, it is thought of as the allergen of
choice for modelling asthma.
The objective was to develop a HDM driven model of asthmatic sensitisation and characterise the role of key
allergic effector cells/mediators.
Methods: Mice were sensitised with low doses of HDM and then subsequently challenged. Cellular inflammation, IgE
and airway responsiveness (AHR) was assessed in wild type mice or CD4+/CD8+ T cells, B cells or IgE knock out mice.
Results: Only those mice sensitised with HDM responded to subsequent low dose topical challenge. Similar to the
classical ovalbumin model, there was no requirement for systemic alum sensitisation. Characterisation of the role of
effector cells demonstrated that the allergic cellular inflammation and AHR was dependent on CD4+ and CD8+ T cells
but not B cells or IgE. Finally, we show that this model, unlike the classic OVA model, appears to be resistant to
developing tolerance.
Conclusions: This CD4+/CD8+ T cell dependent, HDM driven model of allergic asthma exhibits key features of asthma.
Furthermore, we suggest that the ability to repeat challenge with HDM means this model is amenable to studies
exploring the effect of therapeutic dosing in chronic, established disease.
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Background
Asthma is a chronic inflammatory disease of the airways
characterised not only by cellular infiltration into the
airways, but also by an accompanying increase in the sensi-
tivity and response to contractile agents (airway
hyperresponsiveness-AHR) and to allergen exposure (early
and late asthmatic responses) [1, 2]. The global prevalence
of asthma is increasing [3, 4], and the symptoms are often
inadequately controlled [5]. Pre-clinical models which
closely mimic clinical features of asthma are useful to im-
prove our understanding of the mechanisms driving the
disease and thereby the ability to identify novel therapeutic
targets.
Rodent models of experimental allergic asthma to date
have contributed greatly to our current understanding of
the pathogenesis of the disease. However, one of the most
widely used aeroallergens in model development, ovalbu-
min (OVA), is rarely implicated in clinical asthma and is
often used in more acute challenge protocols due to
the development of inhalation tolerance and a dimin-
ishing or complete abrogation of the airway inflam-
matory response following multiple challenges [6–9].
Conventional rodent OVA-models are thought to re-
quire co-administration of an adjuvant to establish suc-
cessful sensitisation. Therefore OVA may not be the most
disease relevant allergen. In contrast, exposure to house
dust mite (HDM), the major source of allergen in house
dust, has been shown to play an important role in asthma
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and also in other allergic diseases such as dermatitis and
rhinitis [10–13]. In the clinic it has been shown that sensi-
tisation to HDM is a strong predictor for asthma and there
is a correlation between the level of HDM exposure and
sensitisation [10, 11]. Because of its clear relevance to hu-
man disease, HDM has in recent years become the allergen
of choice in the development of animal models of asthma
often relying on chronic topical exposure without develop-
ing tolerance [14–19]. However, it is possible that in these
models part of the inflammatory response is due to innate
mechanisms in response to repeat inflammatory insults ra-
ther than allergic mechanisms [20, 21]. We propose that to
fully understand the disease phenotype it is important to
characterise the different stages of the inflammatory re-
sponse in vivo. Therefore the aim of this study was to ini-
tially demonstrate this acute innate response and briefly
investigate the mechanisms involved (i.e. Dectin 1/2 and
TLR 2/4 receptors have been linked to this response) and
then to go on to develop a murine HDM-driven allergic
model based around a separate sensitisation and challenge
protocol. Furthermore we also investigated the role of key
allergic effector cells in features of allergic asthma using this
model. We additionally aimed to compare key features of
this model to a standard OVA-model and investigate its po-
tential for chronic allergen exposures without the associ-
ated tolerance. We suggest the data presented here will
help to elucidate the mechanisms driving the inflammation
observed after acute and chronic HDM exposure and
present targets for possible future therapeutic intervention.
Methods
Animals
Male C57BL/6 mice (16–20 g) were obtained from Harlan
UK Limited (Bicester, UK) and housed with food and water
supplied ad libitum for at least 5 days before beginning
treatments. Genetically modified mice (knockout, KOs)
were back-crossed at least 8 times and bred alongside the
wild type mice: Dectin-1 -/-, Dectin-2 -/-, TLR2 -/-, TLR4-/-,
B cell-/- (JHT mice), CD4 T-cell
-/-, CD8 T-cell -/- and
IgE -/-. Wild-type (WT) mice on a C57bl/6 back-
ground were bred in-house to be used as comparators for
the KO animals. Protocols were approved by the Animal
Welfare and Ethical Review Body (Approval No. PPL 70/
7212), and strictly adhered to the Animals (Scientific Pro-
cedures) Act 1986 UK Home Office guidelines and per-
formed according to the ARRIVE guidelines. Dectin-1 and
Dectin-2 KO mice were donated by Professor Yoichiro
Iwakura, Tokyo University; TLR2, TLR4, B cell, CD4+ T
cell, CD8+ T cell and IgE KO mice were obtained from the
Swiss Immunological Mouse Repository (SwimMR).
House dust mite extract
Purified HDM extract from Dermatophagoides pteronys-
sinus (Der p; lot number 124632; GREER laboratories,
USA) with a known content of Der p1 (12.76 μg/mg dry
weight) was used in these experiments. The doses of
HDM used in this manuscript refer to the amount of
Der p1 delivered.
Materials
All agents were purchased from Sigma-Aldrich (Poole,
UK) unless otherwise stated.
Effect of acute house dust mite
WT mice, TLR2, TLR4, Dectin-1 and Dectin-2 KO mice
were anaesthetised (4 % Isoflurane in oxygen for 3 min,
Abbott Laboratories, UK) and challenged with vehicle
(saline) or HDM extract (25 μg, intratracheally – se-
lected from a previous dose response study). A second
group of WT mice was challenged with protease inacti-
vated HDM (by heating to 65 °C for 30 min as previ-
ously described [20, 22]). WT mice were culled with an
overdose of sodium pentobarbitone (200 mg/kg, i.p.;
Merial, France) 2, 6, 24, 48, 72 or 96 h after challenge
and KO mice at 72 h after challenge. Inflammatory cell
recruitment in the lung was assessed. Briefly, the trachea
was cannulated and bronchoalveolar lavage fluid (BALF)
was obtained via lavage with 0.3 ml RPMI 1640 (Invitro-
gen, UK) 3times. The lavage fluid was pooled. BALF
total white blood cell counts were performed using an
automated cell counter (Sysmex F-820, Sysmex UK Ltd).
Cytospins of BALF was prepared by centrifugation of
100 μl in a cytospin (Shandon, UK) at 700 RPM for
5 min. Slides were subsequently fixed and stained using
a Hema-Tek 2000 (Ames Co., Elkhart, IN) with a modi-
fied Wright-Giemsa stain. Differential counts on 200
cells were performed following standard morphological
criteria and the percentage of eosinophils, neutrophils
and lymphocytes were determined. After lavaging the
airway the lung was removed and the weight recorded.
The lung tissue was then finely chopped and underwent
an enzymatic digest to extract white blood cells. Subse-
quent analysis of white blood cell numbers was performed
as described above.
Development of an allergic HDM driven asthma model
Selection of sensitising dose and sensitisation route
To determine an optimum sensitisation dose and route
a regimen adapted from a previously described OVA
model [23] was used. Topically sensitised WT mice re-
ceived intranasal (i.n.) saline or HDM (50 μl; 0.005–
500 μg/kg) on day 0 and 14. Systemically sensitised WT
mice received intraperitoneal (i.p.) saline, Alum (diluted
1:1 with saline; Pierce Biotechnology Inc, USA), HDM
(0.005–500 μg/kg,) or Alum with HDM (0.005–500 μg/kg)
on day 0 and 14. On day 21, following a sodium pentobar-
bitone (200 mg/kg, i.p.) overdose, heparinised blood sam-
ples were taken by cardiac puncture. Plasma total IgE and
Raemdonck et al. Respiratory Research  (2016) 17:45 Page 2 of 17
IgG1, HDM specific IgE and IgG1 levels were measured by
ELISA.
Selection of challenging dose
Male C57bl/6 mice were sensitised on day 0 and 14 with
saline in Alum or HDM in Alum (0.5 μg/kg, i.p.). Mice
were challenged i.n. with saline or HDM (50 μl; 0.125–
125 μg/kg) on days 24–26. Mice were lavaged 3 days
after the last challenge. BALF total and differential white
blood cell counts were performed as described above.
Determining the need for Alum – HDM and OVA models
HDM model Male C57bl/6 mice were sensitised on day
0 and 14 with saline, Alum, HDM (0.5 μg/kg, i.p.) or
Alum plus HDM (0.5 μg/kg) and challenged i.n. once daily
on days 24–26 with saline or HDM (50 μl; 1.25 μg/kg).
BALF was collected 3 days after the last challenge and
inflammatory cell burden determined.
In a parallel group of mice sensitised with HDM only
(no alum) 3 days after the final HDM challenge, airway
responsiveness to 5-HT was assessed as changes in
enhanced pause (Penh – conscious animals) or airway
resistance (in anaesthetised animals).
Does topical challenge lead to sensitisation? Male
C57bl/6 mice were give saline or HDM (i.n. or i.p.) and
subsequently challenged with saline or HDM as de-
scribed above. 3 days after the final challenge lungs were
lavaged and inflammatory cell burden determined.
OVA model Male C57bl/6 mice were sensitised with
saline, OVA (10 μg/100 μl i.p.), Alum plus saline or
Alum plus OVA (10 μg/100 μl i.p.) on days 0 and 14 and
then challenged i.n. with saline or OVA (50 μg) on days
24–26. Three days after the final OVA challenge airway
responsiveness to 5-HT was assessed as changes in
enhanced pause (Penh – conscious animals). BALF was
collected for assessment of inflammatory cell burden,
plasma samples were harvested and levels of total and
OVA-specific IgE assessed by ELISA.
Chronicity of the HDM model
Male C57bl/6 mice were sensitised on day 0 and 14 with
saline or HDM (0.5 μg/kg, i.p.) and challenged i.n. with sa-
line or HDM (50 μl; 1.25 μg/kg) 3 times a week on con-
secutive days (starting on day 24) for 5 weeks. 3 days after
the final HDM challenge airway responsiveness to 5-HT
and the levels of cellular inflammation in BALF were
assessed as described above. Lung tissue was collected for
pathological assessment (inflammatory score, PAS stain-
ing, collagen deposition and ASM area assessment).
Briefly, lung tissue was fixed with formalin and embedded
in paraffin and multiple 4 uM thick sections cut.
Inflammation staining Slides were stained with aema-
toxylin and eosin (H + E) and placed on the stage of an
Olympus BX51 fluorescence microscope coupled to a
QICAM 1394 camera and colour images were taken.
Analysis was done by a trained person blinded to prior
treatment. Six random areas were selected and each area
was scored for inflammatory burden (0 to 5) and the
data was averaged for each slide and then for each n
number in the group.
Mucus production assessment The slides were stained
with Periodic acid–Schiff (PAS – mucus appears a bright
purple-magenta colour). Assessment was performed
using the protocol outlined above.
Smooth Muscle Area (SMA) Alpha actin was stained
using a primary antibody (Ab-5694, Abcam) and a
secondary antibody (Ab 111-066-003, Jackson Labs).
The staining was revealed using the peroxydase kit from
vector laboratories (DAB Peroxidase (HRP) Substrate
Kit) without Nickel (alpha actin stained in brown). The
slides were counterstained with haematoxylin (blue).
Analysis was performed as described above and
expressed as SMA per airway perimeter.
Collagen deposition assessment Slides were stained
with Sirius Red and counter stained with haematoxylin.
Slides were mounted on an inverted microscope (Zeiss
AxioVert 200 M) equipped with a circularly polariser
and coupled to a Hamamatsu EM-CCD C9100-02 cam-
era. Images were taken in grey tone under polarised light
were collagen stained with Sirius red appears brightly.
Analysis was performed as above and expressed as an
area of collagen per airway perimeter.
Characterisation of the allergic HDM driven asthma model
Profiling a clinically relevant therapy
Mice were sensitised on day 0 and 14 with saline or
HDM (0.5 μg/kg) i.p. and challenged i.n. with saline or
HDM (50 μl; 1.25 μg/kg) on days 24–26. Mice received
an oral dose of vehicle (0.5 % methylcellulose plus 0.2 %
tween 80 in water, 10 ml/kg) or budesonide (3 mg/kg)
twice per day on days 24–28 and also a final dose on
day 29. 3 days after the final HDM challenge airway re-
sponsiveness to 5-HT and the levels of cellular inflam-
mation in BALF were assessed as described above.
Determine the role of key allergic effector cells/mediator
WT, CD4+ T cell, CD8+ T cell, B cell or IgE KO mice were
sensitised on day 0 and 14 with saline or HDM (0.5 μg/kg,
i.p.) and challenged i.n. with saline or HDM (50 μl;
1.25 μg/kg) on days 24–26. 3 Days after the final HDM
challenge airway responsiveness to 5-HT and the levels of
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cellular inflammation in BALF were assessed as described
above.
Data analysis and statistics
Data was expressed as mean ± S.E.M of n observations.
A p value < 0.05 was taken as statistically significant, the
test used is indicated in the figure legends.
Results
Acute HDM challenge
Single topical challenge with HDM (25 μg) caused an
inflammatory signal in naïve, healthy male mice, lasting
up to 96 h after challenge. We observed increases in
neutrophil numbers accompanied by significant increases
in eosinophil, neutrophil and lymphocyte numbers
(Fig. 1a–d) with a similar pattern observed in the lung
tissue (data not shown). Various mechanisms have been
implicated in HDM-driven inflammatory responses in-
cluding the innate protease activity of the allergen [24, 25]
and the activation of various pattern recognition receptors
including TLR2, TLR4, dectin-1 and dectin-2 via the ex-
tract’s co-contaminants such as lipopolysaccharide and β-
glucan moieties [26–30]. When we exposed mice deficient
in TLR2, TLR4, Dectin-1 or Dectin-2 to a single HDM
challenge, only TLR2 and Dectin-2 KO mice showed a
reduced lung tissue inflammatory cell infiltration or a re-
duction in lung tissue weight (Additional file 1: Figure S1).
No changes in BALF inflammatory cell numbers were ob-
served. Due to this direct innate inflammatory response to
the HDM extract we wanted to develop a murine model
with an allergic phenotype i.e. where only allergen sensi-
tised animals respond to allergen challenge.
Development of an allergic HDM driven asthma model
Selection of optimum sensitising route and dose
To optimise the sensitisation phase of the model,
using IgE as a marker of successful sensitisation,
plasma total IgE was measured in mice treated with
various doses of HDM via the intranasal and intraper-
itoneal routes; the latter with or without Alum.
Systemic sensitisation is favoured in the classical
OVA-models, while topical sensitisation with or with-
out the addition of Alum is preferred in HDM-driven
models. Our results show that topical i.n. sensitisation
with HDM failed to induce any changes in total IgE
compared to the respective controls (Fig. 2). In con-
trast, a bell-shaped increase in total IgE was observed
with increasing HDM dose in systemically sensitised
mice both with and without the addition of Alum
compared to their respective controls (Fig. 2). This
increase in total IgE was statistically significant in
mice sensitised with 0.5 μg/kg HDM (both with and
without Alum). At this sensitisation dose we also ob-
served increases in HDM specific IgE, total IgG1 and
HDM specific IgG1 in the plasma (Additional file 2:
Figure S2). For this reason this dose was selected as
the optimum dose to achieve allergic sensitisation in
this model.
Fig. 1 Effect of acute HDM dosing. Naïve male C57bl/6 mice were anaesthetised (4 % isoflurane in oxygen for 3 min) and challenged with i.t. saline or
HDM. 2, 6, 24, 48, 72 and 96 h after challenge the lungs were lavaged and BALF eosinophil (a), neutrophil (b), lymphocyte (c) and total white cells
(d) numbers were determined. Data (n = 6) expressed as mean cell numbers (103/ml) ± S.E.M. *p < 0.05 vs. respective saline challenged time matched
controls, Mann-Whitney U-test
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Selection of optimum challenging dose
In this next phase we performed a dose response to in-
tranasal allergen challenge in sensitised mice to establish
a challenge dose which caused airway inflammation only
in mice previously sensitised to HDM. As previous re-
sults suggested (Fig. 1), high doses of HDM (12.5 and/or
125 μg/kg HDM) significantly increased the number of
BALF lymphocytes and neutrophils compared to saline-
challenged controls without the need for prior allergen
sensitisation (Fig. 3b and c). In contrast, low dose i.n.
HDM challenge (1.25 μg/kg) in allergen sensitised mice
caused a significant increase in BALF eosinophil,
lymphocyte and neutrophil numbers, but importantly
was not observed in mice which had not previously been
exposed to HDM (Fig. 3). Due to this requirement of
prior sensitisation to elicit an inflammatory response,
the dose of 1.25 μg/kg HDM was selected as the chal-
lenge dose for the allergic HDM model. This dose
induced sub-maximal levels of cellular inflammation in
the BALF characterised by an influx of eosinophils, lym-
phocytes and macrophages without an accompanying
non-allergic cellular inflammation.
Does topical challenge lead to sensitisation?
As we show in Fig. 2, in our hands intranasal sensitisation
did not result in measurable changes in the levels of
plasma IgE. The current trend in HDM model develop-
ment has been to adopt experimental protocols employing
repeated topical intranasal sensitisation with HDM
followed by repeated topical intranasal HDM challenge,
rather than the more traditional approach with distinct
sensitisation and challenge phases. In our hands however,
intranasal HDM challenge in mice topically sensitised
with HDM did not result in an inflammatory cell influx
into the BALF (Additional file 3: Figure S3). Mice sub-
jected to our systemic i.p. sensitisation and topical i.n.
challenge protocol, as shown previously (Fig. 3), mounted
a robust inflammatory response as measured by increases
in the number of eosinophils, neutrophils and lympho-
cytes in BALF (Additional file 3: Figure S3).
Determining the need for Alum
As was shown in Fig. 2 an exogenous adjuvant was not
necessary to achieve an increase in plasma total IgE after
systemic sensitisation with HDM. The question
remained as to whether Alum actually is needed during
sensitisation in this model in order for an allergic
response to occur after HDM challenge. Interestingly, i.n
HDM challenge (1.25 μg/kg) in mice systemically sensi-
tised to HDM with or without Alum induced statistically
significant increases in the levels of BALF eosinophils,
lymphocytes and neutrophils (Fig. 4). This clearly shows
that Alum is not required to sensitise the mice to re-
spond to a subsequent HDM challenge. Therefore, all
experiments looking into the AHR, key effectors cells
and mediators were performed without the use of the
exogenous adjuvant Alum. In an OVA-dependent aller-
gic mouse model of asthma, adopting the same sensitisa-
tion and challenge protocol used in the HDM-model, we
show that despite the widespread use of adjuvants in
conjunction with this allergen, Alum was not required
to induce an allergic inflammatory response in the BALF
characterised by an influx of eosinophils, neutrophils
and lymphocytes (Additional file 4: Figure S4). In
addition, OVA was able, without the addition of Alum,
to induce robust total and OVA-specific IgE plasma
Fig. 2 Selection of optimum sensitising route and dose. Male C57bl/6 mice were sensitised with vehicle or HDM (0.005–500 μg/kg HDM) either i.n.
or i.p. (with or without Alum). Levels of total IgE in plasma were measured by ELISA. The dose and route selected for further model investigation is
indicated by the black arrow. Data (n = 6–12) expressed as mean total IgE levels (ng/ml) ± S.E.M. *p < 0.05 vs. respective saline challenged controls,
Kruskal-Wallis one-way ANOVA followed by Dunn’s Multiple Comparison post-test
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levels (Additional file 5: Figure S5A and B) and AHR to
5-HT (Additional file 5: Figure S5C).
Airway function in HDM model
Functional endpoints such as AHR are very important
to determine the usefulness of preclinical models of
asthma. AHR in this HDM model was assessed 3 days
after final HDM challenge as increases in airflow
obstruction to aerosolised 5-HT measured by Penh. In
HDM-sensitised and -challenged conscious mice the
increase in airway responses to inhaled 5-HT was
significantly enhanced compared to HDM-sensitised and
saline-challenged control mice (Fig. 5). This phenomenon
was mirrored when we recorded changes in resistance
after aerosolised 5-HT in anaesthetised mice (Additional
file 6: Figure S6).
Chronic HDM exposure
Chronic exposure of surrogate allergens such as OVA in
animal models of asthma often leads to the development
of tolerance [6–9]. This acquired tolerance hinders the
investigation of underlying pathways and of the chron-
icity of the disease. Intermittent allergen exposure has
been suggested to be able to overcome the development
of tolerance [31, 32]. In our model, the exposure of
previously sensitised mice to i.n. HDM 3 times a week
for 5 weeks resulted in significantly increased eosinophil
and lymphocyte numbers in BALF when compared to
the respective control animals (Fig. 6a–c). While stand-
ard OVA models following chronic exposures often
report diminished inflammatory responses, the increase
in BALF inflammatory cells following chronic HDM
challenge was persistent, possibly attributable to the
intermittent challenge protocol employed. In addition,
this inflammatory response was accompanied by a
robust increase in airway responses to inhaled 5-HT
(Fig. 6e). This inflammation in the BALF was associated
with pathological changes in the lung tissue (Additional
file 7: Figure S7).
Characterisation of the allergic HDM driven asthma model
Profiling a clinically relevant therapy
Exposing WT mice to the selected HDM sensitisation
and challenge protocol led to significantly increased
levels of neutrophils, eosinophils and lymphocytes in
BALF and AHR in response to 5-HT (Figs. 4, 5 and 7).
As expected pre-treatment with oral budesonide, a
glucocorticosteroid, effectively and significantly inhibited
the BALF inflammatory response and the increased
airway response to 5-HT (Fig. 7a–e).
Fig. 3 Selection of optimum challenging dose. Male C57bl/6 mice were sensitised with saline or HDM in the presence of Alum and challenged
i.n. with saline or HDM (0.125–125 μg/kg HDM). 72 h after challenge the lungs were lavaged and BALF eosinophil (a), neutrophil (b), lymphocyte
(c) and total white cell (d) numbers were determined. The dose selected for further model investigation is indicated by the black arrow. Data
(n = 7–8) expressed as mean cell numbers (103/ml) ± S.E.M. *p < 0.05 vs. relevant saline-challenged controls, Kruskal-Wallis one-way ANOVA
followed by Dunn’s Multiple Comparison post-test
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Fig. 5 Effect of HDM sensitisation and challenge on airway responsiveness to inhaled 5-HT. Male C57bl/6 mice were sensitised with saline or HDM
(no Alum) and subsequently challenged with saline or HDM. Conscious mice were placed in WBP chambers 3 days after final HDM challenge and
airway responsiveness to inhaled 5-HT was assessed as Penh. Data (n = 6) expressed as mean Penh AUC ± S.E.M. *p < 0.05 vs. HDM-sensitised/saline-
challenged controls, Mann-Whitney U-test
Fig. 4 The requirement for Alum during sensitisation in the allergic inflammatory response to HDM challenge. Male C57bl/6 mice were sensitised
with saline or HDM in the presence or absence of Alum. Mice were subsequently challenged with saline (open bars) or HDM (grey bars). 3 days after
challenge the lungs were lavaged and BALF eosinophil (a), neutrophil (b), lymphocyte (c) and total white cell (d) numbers were determined. Data
(n = 6) expressed as mean cell numbers (103/ml) ± S.E.M. *p < 0.05 vs. relevant HDM sensitised/saline-challenged controls, Mann-Whitney U-test
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Determine the role of key allergic effector cells/mediators
Antigen challenge led to significantly increased levels of
neutrophils, eosinophils and lymphocytes in BALF and
AHR in response to 5-HT in WT mice (Figs. 8, 9, 10 and
11). In mice lacking functional CD4+ T cells or CD8+ T
cells both the BALF cellular inflammation and the in-
creased airway response to spasmogen were significantly
reduced compared to allergic WT mice (Figs. 8 and 9a–d).
In contrast, those mice missing functional B cells or with
impaired IgE responses were able to mount an inflamma-
tory response following HDM sensitisation and challenge
similar to the response observed in allergic WT mice
(Figs. 10 and 11a–d). This was associated with AHR to 5-
HT (Figs. 10 and 11e). B cell KO mice did exhibit a
reduced number of BALF lymphocytes (Fig. 10c), though
this did not reach control levels and possibly reflects the
lack of B cells themselves. These data suggest that while T
cells are vital to the inflammation and AHR observed in
this model, this response to HDM can occur independ-
ently from both B cells and IgE.
Discussion
Pre-clinical models closely mimicking the cardinal fea-
tures of asthma are useful in understanding the mecha-
nisms driving the disease and can help in identifying novel
therapeutic targets. Traditional models of allergic asthma
involve the use of OVA along with adjuvants such as
Alum and have been profiled extensively. Yet, these
Fig. 6 The effect of chronic HDM exposure on airway inflammation and airway responsiveness to inhaled 5-HT. Male WT C57bl/6 mice were sensitised
with saline or HDM and subsequently challenged with saline or HDM 3 times a week for 5 weeks. Mice were placed in WBP chambers 3 days after final
HDM challenge and airway responsiveness to inhaled 5-HT was assessed as Penh (e). Data (n= 6) expressed as mean Penh AUC± S.E.M. Immediately after
AHR assessment the lungs were lavaged and BALF eosinophil (a), neutrophil (b), lymphocyte (c) and total white cell (d) numbers were determined. Data
(n= 6) expressed as mean cell number (103/ml) ± S.E.M. *p< 0.05 vs. HDM sensitised, saline challenged controls, Mann-Whitney U-test
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models have limitations. On the other hand, HDM is
increasingly being used as a disease-relevant antigen in
rodent models of allergic airway inflammation since it
does not require an adjuvant and is not linked to the
development of inhalation tolerance [15–18]. However,
previous studies have suggested that part of the airway
inflammation observed in response to topical HDM is due
to innate rather than allergic mechanisms [20, 21]. There-
fore, to fully understand the disease phenotype and
extrapolate in vivo data to the clinic, we suggest it is ne-
cessary to clearly distinguish between the events under-
lying sensitisation and challenge, and characterise all
stages of the allergic inflammatory response in vivo. In the
present study, we describe an in vivo mouse model of
HDM-induced allergic asthma with a distinct sensitisation
and challenge phase characterised by allergen induced
airway inflammation and AHR dependent on CD4+ and
CD8+ T cells, but not B cells or IgE. This inflammation
and AHR was sensitive to treatment with systemic steroids
showing the model to be relevant to clinical asthma. In
addition this model exhibits persistent airway inflamma-
tion and AHR following chronic exposure to the allergen.
A single topical exposure to HDM caused robust
inflammatory cell recruitment into the mouse airway.
Although the prominent cell type was neutrophils we
could also detect an increase in eosinophils and lympho-
cytes (Fig. 1). This can be recapitulated in the rat [20]
and thus far the mechanism underlying this innate re-
sponse remains unclear. HDM extracts have been shown
to contain various other contaminants capable of activat-
ing inflammatory pathways [33–35]. Our data exclude a
role for HDM innate protease activity, TLR4 and
Fig. 7 Effect of budesonide on HDM induced airway inflammation and airway responsiveness to inhaled 5-HT. Male C57bl/6 mice were sensitised
with HDM, and subsequently challenged with saline or HDM. Mice were treated with vehicle (0.5 % methylcellulose plus 0.2 % tween80 in water)
or budesonide (3 mg/kg). Mice were placed in WBP chambers 3 days after final HDM challenge and airway responsiveness to inhaled 5-HT was
assessed as Penh (e). Data (n = 12) expressed as mean Penh AUC ± S.E.M. Immediately after AHR assessment the lungs were lavaged and BALF
eosinophil (a), neutrophil (b), lymphocyte (c) and total white cell (d) numbers were determined. Data (n = 12) expressed as mean cell number
(103/ml) ± S.E.M. #p < 0.05 vs. relevant HDM-sensitised/saline-challenged controls, Mann-Whitney U-test. *p < 0.05 vs. relevant challenged/vehicle-
treated controls, Mann-Whitney U-test
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Dectin-1 (Additional file 1: Figure S1) activation in this
response despite previous studies implicating these fac-
tors in HDM-mediated inflammatory responses [24–26,
28], but show that there is a potential involvement of
TLR2 and Dectin-2 (Additional file 1: Figure S1) in
accordance with previous reports [27–30]. Although this
falls outside the scope of the current publication, we
suggest that further investigation of this underlying
mechanism driving acute HDM-induced inflammation
will lead to a better understanding of animal models,
and could potentially uncover disease relevant mecha-
nisms involved in the pathogenesis of asthma.
This apparent innate inflammatory response to HDM
could confound the understanding of mechanisms
underlying asthma-like features in animal models and
complicate extrapolation of results to the clinic. We
therefore developed a HDM-driven murine model in
which airway inflammation and AHR only occurred in
animals which had been previously sensitised to HDM.
Using direct comparison studies we demonstrated that
Alum during the sensitisation stage was not required for
the allergic airway inflammation and AHR observed in
this HDM model (Figs. 4 and 5). This is a great advan-
tage as it avoids the use of an exogenous adjuvant and
more closely resembles the allergenic cocktail to which
patients are exposed. HDM has been demonstrated to
possess innate adjuvant capacity and as such the fact
that an exogenous adjuvant was not required for suc-
cessful sensitisation or for the development of allergic
asthma following allergen exposure, is not surprising.
Interestingly, we also show that an adjuvant was not
required for the production of OVA-specific IgE or the
induction of airway inflammation and AHR in an OVA-
dependent murine model (Additional file 4: Figure S4 and
Additional file 5: Figure S5). This is surprising when one
considers current dogma and that the majority of pub-
lished models suggest that the OVA model requires the
use of a systemic adjuvant to induce allergic sensitisation.
Despite being widely criticised for not being clinically rele-
vant and although adjuvant-free OVA models have been
described [36–38] adjuvant dependent OVA-models con-
tinue to be used in the field. It has been noted that OVA
is contaminated with lipopolysaccharide which might
account for some of its auto-adjuvant properties [39].
Fig. 8 The role of CD4+ T-cells in HDM induced airway inflammation and airway responsiveness to inhaled 5-HT. Male WT C57bl/6 and CD4+ T-cell KO
mice were sensitised with HDM and subsequently challenged with saline or HDM. Mice were placed in WBP chambers 3 days after final HDM challenge
and airway responsiveness to inhaled 5-HT was assessed as Penh (e). Data (n= 7–8) expressed as mean Penh AUC± S.E.M. Immediately after AHR
assessment the lungs were lavaged and BALF eosinophil (a), neutrophil (b), lymphocyte (c) and total white cell (d) numbers were determined. Data
(n= 7–8) expressed as mean cell number (103/ml) ± S.E.M. *p < 0.05 vs. relevant saline-challenged controls, Mann-Whitney U-test. #p < 0.05 vs. challenged
WT controls, Mann-Whitney U-test
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Our results also highlight the importance of choosing
the appropriate route for allergen delivery. Although
several murine models utilising systemic sensitisation
have been described [40, 41], the majority of research
groups that utilise HDM-driven murine models cur-
rently favour topical sensitisation rather than systemic
routes [14–19]. However, in contrast to these published
models, this new HDM model uses systemic allergen
sensitisation with a full HDM extract with all its associ-
ated contaminants without the need for an adjuvant. It
is currently accepted that asthmatics become sensitised
to HDM and other aeroallergens through the airways.
However, several other mechanisms can lead to sensi-
tisation and the development of allergic airways disease.
Infants may have some features of allergy at birth
through prenatal in-utero sensitisation [42–44]. In
addition, in those atopic patients whereby atopic derma-
titis is developed early on, followed by allergic rhinitis
and subsequently atopic asthma later in life systemic
sensitisation seems more likely, rather than sensitisation
through airway exposure [45–47]. The fact that not
every person exposed to HDM becomes sensitised and
develops allergic asthma suggests that an animal model
where allergen exposure only elicits a response in previ-
ously sensitised animals seems preferable. In contrast to
reports that Balb/c mice can be primed to respond to
HDM challenges via intranasal sensitisation [48] in our
hands in this C57BL/6 murine model this did not occur
(Fig. 2 and Additional file 3: Figure S3) and thus sup-
ports our use of systemic sensitisation during model
development.
Due to the difficulty developing appropriate models
capable of recapitulating key features of chronic asthma,
the mechanisms underlying the chronicity of the disease
have been far less investigated when compared to acute,
immediate responses. The common allergen, OVA, fre-
quently used in model development has been reported by
many groups following chronic exposure protocols to
result in inhalation tolerance and the abrogation of the
inflammatory airway response [6–9]. It has been suggested
that intermittent allergen exposures over prolonged pe-
riods of time do not result in the development of tolerance
[31, 32]. Our data show that the administration of HDM
over the course of 5 weeks in the absence of exogenous
Fig. 9 The role of CD8+ T-cells in HDM induced airway inflammation and airway responsiveness to inhaled 5-HT. Male WT C57bl/6 and CD8+ T-cell KO
mice were sensitised with HDM and subsequently challenged with saline or HDM. Mice were placed in WBP chambers 3 days after final HDM challenge
and airway responsiveness to inhaled 5-HT was assessed as Penh (e). Data (n= 6–7) expressed as mean Penh AUC± S.E.M. Immediately after AHR
assessment the lungs were lavaged and BALF eosinophil (a), neutrophil (b), lymphocyte (c) and total white cell (d) numbers were determined. Data
(n= 6–7) expressed as mean cell number (103/ml) ± S.E.M. *p < 0.05 vs. relevant saline-challenged controls, Mann-Whitney U-test. #p < 0.05 vs. challenged
WT controls, Mann-Whitney U-test
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adjuvants does not lead to tolerance but a robust inflam-
matory response in HDM sensitised animals characterised
by persistent airway eosinophilic, neutrophilic and lympho-
cytic airway infiltration accompanied by AHR to 5-HT
(Fig. 6). It is plausible that the robust allergic response in
our model is attributable to the non-continuous allergen
exposure protocol. These results parallel data collected in
those models employing chronic topical HDM challenges
[18–23] and highlight the feasibility of using HDM to
model chronic disease symptoms and the potential of the
model to be used to assess the effect of new therapeutics
dosed prophylactically and therapeutically in established
‘disease’ conditions.
HDM sensitisation induced the production of total
and specific IgE (Fig. 2 and Additional file 2: Figure S2).
Decades of research have implicated IgE-mediated
responses in asthma and IgE is now a key target for
asthma therapy. However, some have argued that
increases in measurable IgE could be merely a result of
asthma i.e. a marker of inflammation [49]. Additionally,
studies utilising IgE directed therapy have shown mixed
results [50]. Thus, IgE independent mechanisms have
been suggested to also contribute to allergic disease
[13, 51–53]. Through the use of KO mice deficient in
IgE and functional B cells, our findings suggest that,
at least in this model, IgE and B cells are not required for
the generation of immune responses in animals systemic-
ally sensitised with and topically exposed to HDM (Figs. 10
and 11). This is in accordance with the suggestion that
HDM can contribute to allergic disease independent of
IgE, but is in contrast with a recent publication showing
that mice, deficient in B cells, repeatedly exposed to an
allergenic cocktail of HDM, Alternaria and Aspergillus
exhibited reduced airway inflammation, lung pathology
and AHR [54]. However, it is likely that the different aller-
gens administered can act through different pathways
some of which might indeed be independent of B cells
and IgE production [55–58]. Furthermore, existing experi-
mental model data, in contrast to these observations, sug-
gested that the role of B cells in allergen induced immune
responses may depend on the route of allergen delivery
and on the type of allergen used [54, 58]. This could
account for the differences with our model and the diver-
gent data regarding the role of B cells in the regulation of
Fig. 10 The role of B cells in HDM induced airway inflammation and airway responsiveness to inhaled 5-HT. Male WT C57bl/6 and B cell KO mice
were sensitised with HDM and subsequently challenged with saline or HDM. Mice were placed in WBP chambers 3 days after final HDM challenge
and airway responsiveness to inhaled 5-HT was assessed as Penh (e). Data (n = 6–9) expressed as mean Penh AUC ± S.E.M. Immediately after AHR
assessment the lungs were lavaged and BALF eosinophil (a), neutrophil (b), lymphocyte (c) and total white cell (d) numbers were determined.
Data (n = 6–9) expressed as mean cell number (103/ml) ± S.E.M. *p < 0.05 vs. relevant saline-challenged controls, Mann-Whitney U-test. #p < 0.05
vs. challenged WT controls, Mann-Whitney U-test
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immune responses to various allergens. Moreover, we
show that the airway inflammatory response and associ-
ated AHR in this model is T cell dependent as CD8+ and
CD4+ T cell KO mice failed to develop a response distin-
guishable from WT saline exposed control mice (Figs. 8
and 9). In the clinic elevated numbers of lymphocytes cor-
relate with eosinophilia and asthma severity and this lym-
phocytosis has been shown to include both CD4+ and
CD8+ T cells [59–61]. The CD4+ T cell is thought to be the
dominant active T cell subtype in clinical allergic asthma as
well as in animal models of asthma [57, 60, 62–64]. In con-
trast, the role of CD8+ T cells both in human asthma and
animal models of allergic disease remains controversial,
having been reported to be both protective or deleterious
[65]. Supporting our data however, an increase in airway
CD8+ T cells following allergen challenge predicts annual
FEV1 decline in asthmatic patients [66, 67] and increased
numbers can be found in patients following a fatal asthma
attack [68, 69].
It is clear from published experimental data that CD4+
and CD8+ T cells can contribute to AHR development
and allergic inflammation. However, the interpretation
of their role and importance during sensitisation and/or
challenge across various different models can vary
largely. It is well established that CD4+ T cells are re-
quired during sensitisation [57, 70, 71]. Reconstitution
of CD4+ T cells alone in RAG-/- mice, deficient in both
T-and B-cells, prior to sensitisation was sufficient for
Aspergillus fumigatus-induced AHR and airway inflam-
mation [57]. Interestingly, while CD8+ T cells were not
required, this observation was also dependent on IL-4.
Additionally, CD4+ T cell depletion before allergen chal-
lenge resulted in reduced AHR and airway eosinophilia
[62] suggesting they are indeed crucial for the develop-
ment of allergen induced airway disease. CD8+ T cells
can differentiate, under the right conditions, in separate
subsets [72–75]. It has been argued that these different
subsets within different models could be responsible for
the contradictory reports. Specific depletion of CD8+ T
cells in sensitised rats enhanced the airway inflammation
and related late asthmatic responses [76] and in addition
augmented airway remodelling and mucus production.
[77, 78]. Similarly, certain CD8+ T cell subsets have been
shown to prevent OVA-induced inflammation in mice
Fig. 11 The role of IgE in HDM induced airway inflammation and airway responsiveness to inhaled 5-HT. Male WT C57bl/6 and IgE KO mice were
sensitised with HDM and subsequently challenged with saline or HDM. Mice were placed in WBP chambers 3 days after final HDM challenge and
airway responsiveness to inhaled 5-HT was assessed as Penh (e). Data (n = 8) expressed as mean Penh AUC ± S.E.M. Immediately after AHR assessment
the lungs were lavaged and BALF eosinophil (a), neutrophil (b), lymphocyte (c) and total white cell (d) numbers were determined. Data (n = 8)
expressed as mean cell number (103/ml) ± S.E.M. *p < 0.05 vs. relevant saline-challenged controls, Mann-Whitney U-test. #p < 0.05 vs. challenged WT
controls, Mann-Whitney U-test
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[79, 80]. Others have shown that CD4+, but not CD8+ T
cells are required for allergic airway responses [57, 81].
In contrast, a body of work by Gelfand and colleagues
[70, 71, 82, 83] using mainly a systemic sensitisation and
topical challenge OVA mouse model of allergic asthma
corroborates our results in this HDM model and high-
lights a role for both CD8+ and CD4+ T cells in AHR
and airway inflammation. Using a variety of adoptive cell
transfer studies and KO mice, they demonstrated the
activation of allergen primed CD8+ T cells and IL-13
production within the airway [71, 83] critical for AHR
and airway inflammation in this model. Additionally,
their data suggest that CD4+ T cells and IL-4 are crucial
during sensitisation for CD8+ T cell activation [70].
More recent publications also highlighted a possible role
for IL-13 producing CD8+ T cell populations in aug-
mented allergen driven inflammatory responses even in
the absence of prior sensitisation [84]. It would be inter-
esting to see whether similar pathways underlie the AHR
and airway inflammation in our HDM model and merits
further investigation. It is likely that a close interaction
between CD4+ and CD8+ T cells is key to driving the al-
lergic responses within our HDM model.
Conclusion
In summary, we have developed a murine model of aller-
gic asthma characterised by allergic airway inflammation
and AHR which is dependent on prior allergen sensitisa-
tion without the need for an exogenous adjuvant. We
show that this inflammation and AHR is dependent on
CD4+ and CD8+ T cells and is persistent following mul-
tiple challenges. Our data reinforce the notion that T
cells play a pivotal role in orchestrating pathological and
physiological changes observed in human asthma. This
newly developed model holds advantage over models that
utilise topical administration in isolation in that sensitisa-
tion and challenge phases can be easily distinguished
which allows separate interrogation. Additionally, with the
possibility of repeat challenges this model could be useful
in studies exploring therapeutic interventions in estab-
lished chronic disease.
Additional files
Additional file 1: Figure S1. Investigation of mechanism driving acute
inflammatory response to HDM challenge. Naïve male C57bl/6, TLR2,
TLR4, Dectin-1 and Dectin-2 KO mice were anaesthetised (4 % isoflurane
in oxygen for 3 min) and challenged with i.t. vehicle (saline) or HDM
(25 μg/mice in 50 μl saline). 48 h after challenge the lungs were lavaged,
lung weight (A) determined, BALF (B) and lung tissue (C) total white blood
cell numbers (D) were determined. Data (n = 7–8) expressed as means ±
S.E.M. *p < 0.05 vs saline challenged controls (Mann-Whitney test). #p < 0.05
vs. challenged WT controls, Mann-Whitney U-test. (DOC 185 kb)
Additional file 2: Figure S2. Ig levels in response to sensitisation with
HDM via different routes. Male C57bl/6 mice were sensitised with vehicle
or HDM (5 μg/kg HDM) either i.n. or i.p. (with or without Alum). Levels of
HDM-specific IgE (A), total IgG1 (B) and HDM-specific IgG1 (C) in plasma were
measured by ELISA. Data (n = 6) expressed as means ± S.E.M. *p < 0.05 vs.
respective saline challenged controls, Mann-Whitney U-test. (DOC 183 kb)
Additional file 3: Figure S3. The effect of intranasal HDM challenge in
topically sensitised mice. Male C57bl/6 mice were sensitised i.n. or i.p. as
indicated below the figures with saline or HDM. Mice were subsequently
challenged with saline or HDM. 3 days after the last challenge lungs were
lavaged and BALF eosinophil (A), neutrophil (B) and lymphocyte (C)
numbers were determined. Data (n = 8–12) expressed as mean cell
number (103/ml) ± S.E.M. *p < 0.05 vs. relevant saline sensitised controls,
Mann-Whitney U-test. (DOC 109 kb)
Additional file 4: Figure S4. The requirement for Alum during
sensitisation in the allergic inflammatory response to OVA challenge.
Male C57bl/6 mice were sensitised with saline or OVA made up in saline
or Alum as indicated below the figure. Mice were subsequently challenged
with saline (white bars) or OVA (grey bars). 3 days after the last challenge
lungs were lavaged and BAL fluid eosinophil (A), neutrophil (B), lymphocyte
(C) and total white blood cell (D) numbers were determined. Data
expressed as mean cell number (103/ml) ± S.E.M. (n = 7–9). *p < 0.05 vs.
relevant saline challenged controls, Mann-Whitney U-test. (DOC 177 kb)
Additional file 5: Figure S5. Alum-independent OVA-induced airway
hyperresponsiveness to 5-HT and IgE production. Male C57Bl/6 mice were
sensitised with saline or OVA in the presence or absence of Alum and
subsequently challenged with saline or OVA. Animals sensitised in the
absence of Alum were placed in WBP chambers and airway responsiveness
to 5-HT was assessed 3 days after final challenge (C). Data (n = 7–9) was
expressed as mean Penh AUC ± S.E.M. Plasma levels of total IgE (A) and
OVA-specific IgE (B) were assessed by ELISA 3 days after final OVA challenge.
Data (n = 7–9) expressed as mean ± S.E.M. *p < 0.05 vs. relevant OVA
sensitised/saline challenged controls, Mann-Whitney U-test. (DOC 168 kb)
Additional file 6: Figure S6. Effect of HDM sensitisation and challenge
on airway responsiveness to inhaled 5-HT. Male C57bl/6 mice were
sensitised with saline or HDM (no Alum) and subsequently challenged
with saline or HDM. Anaesthetised mice were instrumented and airway
responsiveness to inhaled 5-HT was assessed by changes in resistance.
Data (n = 6) expressed as mean resistance ± S.E.M. (DOC 150 kb)
Additional file 7: Figure S7. The effect of chronic HDM exposure on
airway pathology. Male WT C57bl/6 mice were sensitised with saline or
HDM and subsequently challenged with HDM 3 times a weeks for 5 weeks.
Mice were culled 3 days after final HDM challenge and the lungs collected
and assessed for inflammatory status: A) example H&E staining from the
control group; B) example H&E staining from the allergic HDM challenged
group; C) inflammatory cell burden score; D) mucus production (PAS
staining) score; E) collagen deposition (Sirius Red staining) and F) airway
smooth muscle area (alpha acting staining). Data (n = 6) expressed as
mean ± S.E.M. #p < 0.05, Mann-Whitney U-test. (DOC 940 kb)
Abbreviations
5-HT: 5-hydroxytryptamine; AHR: airway hyperresponsiveness; Alum: 20 mg/ml
aluminium hydroxide and 20 mg/ml; AUC: area under the curve;
BALF: bronchoalveolar lavage fluid; BSA: bovine serum albumin; CD: cluster of
differentiation; ELISA: enzyme-linked immunosorbent assay; FEV1: forced
expiratory volume in 1 s; HDM: house dust mite; HRP: horseradish peroxidase;
i.n.: intranasal; i.p.: intraperitoneal; i.t.: intratracheal; IgE: immunoglobulin E;
IL: interleukin; KO: knockout; OVA: ovalbumin; PBS: phosphate buffered saline;
Penh: enhanced pause; S.E.M.: standard error of the mean; TLR: Toll-like
receptor; TMB: 3,3′,5,5′-Tetramethylbenzidine; WBP: whole body
plethysmograph; WT: wild type.
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